Breaking News
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia
The New Issue of the TIF Newsletter Is Just Released
TIF Newsletter – December 2020
Just Updated: TIF’s Vaccinations & Therapeutic Drugs for COVID-19 Guide
Iranian Blood Transfusion Organization Newsletter – December 2020
Blood Under The Microscope Of The European Commission: An Article by TIF’s Executive Director
THALIA App: The Skilled Digital Assistant of People with Thalassaemia and Sickle Cell Disease
COVID-19 Vaccines and Haemoglobin Disorders: The Latest Position Statement of the Thalassaemia International Federation
English
Ελληνικά
Français
Deutsch
Italiano
العربية
Menu
Search for
RSS
Instagram
YouTube
Twitter
Facebook
Home
/
What we do
What we do
Coming soon…
Back to top button
Close
Search for
Close
Log In
Forget?
Remember me
Log In
Cookies
This site uses cookies.
Find out more
Okay, thanks
